WO2004033652A2 - Inhibitors of fatty acid amide hydrolase - Google Patents
Inhibitors of fatty acid amide hydrolase Download PDFInfo
- Publication number
- WO2004033652A2 WO2004033652A2 PCT/US2003/031975 US0331975W WO2004033652A2 WO 2004033652 A2 WO2004033652 A2 WO 2004033652A2 US 0331975 W US0331975 W US 0331975W WO 2004033652 A2 WO2004033652 A2 WO 2004033652A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subunit
- group
- fatty acid
- mmol
- acid amide
- Prior art date
Links
- 0 CCCC(CC)C1=N*(*)=C(*)*1 Chemical compound CCCC(CC)C1=N*(*)=C(*)*1 0.000 description 10
- VMVNFVMIKMIETB-UHFFFAOYSA-N CCC(C)c1ncc[o]1 Chemical compound CCC(C)c1ncc[o]1 VMVNFVMIKMIETB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to inhibitors of fatty acid hydrolase. More particularly, the invention relates to inhibitors of fatty acid hydrolase of the type having a heterocyclic head group attached to a tail region.
- Fatty acid amide hydrolase is an integral membrane protein that hydrolyzes a wide range of oleyl and arachidonyl amides, the CB1 agonist
- 2-arachidonyIglycerol the related 1-arachidonylglycerol and 1-oleylglycerol, and methyl arachidonate, illustrating a range of bioactive fatty acid amide or ester substrates.
- a class of FAAH inhibitor represented by the formula A-B-C has been disclosed by Dale Boger (US Patent No. 6,462,054).
- A is an - keto heterocyclic pharmacophore for inhibiting the fatty acid amide hydrolase
- B is a chain for linking A and C, said chain having a linear skeleton of between 3 and 9 atoms selected from the group consisting of carbon, oxygen, sulfur, and nitrogen, the linear skeleton having a first end and a second end, the first end being covalently bonded to the ⁇ -keto group of A, with the following proviso: if the first end of said chain is an ⁇ -carbon with respect to the ⁇ -keto group of A, then the ⁇ -carbon is optionally mono- or bis-functionalized with substituents selected from the group consisting of fluoro, chloro, hydroxyl, alkoxy, trifluoromethyl, and alkyl; and C is a binding subunit for binding to FAAH and enhancing the inhibition activity of said ⁇ -
- FAAH inhibitors having a head group attached to a tail region, the head group having one or more heterocycles for achieving enhanced activity with respect to the inhibition of fatty acid amide hydrolase.
- the invention is directed to improved competitive inhibitors of FAAH that employ an ⁇ -keto heterocyclic pharmacophore and a binding subunit having a ⁇ - unsaturation.
- the ⁇ -keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferably by a hydrocarbon chain.
- the improvement lies in the use of a heterocyclic pharmacophore selected from oxazoles, oxadiazoles, thiazoles, and thiadiazoles that include alkyl or aryl substituents at their 4 and/or 5 positions.
- the improved competitive inhibitors of FAAH display enhanced activity over conventional competitive inhibitors of FAAH.
- One aspect of the invention is directed to an inhibitor of fatty acid amide hydrolase represented by the following formula:
- A is an inhibition subunit
- B is a linkage subunit
- C is a binding subunit
- the inhibition subunit A is an ⁇ -keto heterocyclic pharmacophore for inhibiting the fatty acid amide hydrolase.
- the ⁇ -keto heterocyclic pharmacophore being represented by the following formula:
- X is selected from the group consisting of carbon and nitrogen;
- Y is selected from the group consisting of oxygen and sulfur;
- R 1 and R 2 are radicals independently selected from the group consisting of hydrogen, C1-C6 alkyl, aromatic ring, and heteroaromatic ring.
- R 1 and R 2 are radicals independently selected from the group consisting of hydrogen, C1-C6 alkyl, and radicals represented by the following structures:
- R 1 and R 2 cannot both be hydrogen; and 2.) if X is nitrogen, R 1 is absent.
- the linkage subunit B is a chain for linking the inhibition subunit A and the binding subunit C and for enabling the binding subunit C to bind to the binding region on the fatty acid amide hydrolase while the inhibition subunit A simultaneously inhibits the fatty acid amide hydrolase.
- the chain has a linear skeleton of between 3 and 9 atoms selected from the group consisting of carbon, oxygen, sulfur, and nitrogen, the linear skeleton having a first end and a second end, the first end being covalently bonded to the ⁇ -keto group of A.
- the ⁇ -carbon is optionally mono- or bis-functionalized with substituents selected from the group consisting of fluoro, chloro, hydroxyl, alkoxy, trifluoromethyl, and alkyl.
- the binding subunit C is a ⁇ -bond containing radical having a ⁇ - unsaturation.
- the binding subunit C is selected from a group consisting of aryl, alkenyl, alkynyl, and ring structures having at least one unsaturation, with or without one or more heteroatoms.
- the binding subunit C is covalently bonded to the second end of the linkage subunit B.
- the ⁇ -unsaturation within the ⁇ -bond containing radical is separated from the ⁇ -keto group of A by a sequence of no less than 3 and no more than 9 atoms bonded sequentially to one another, inclusive of the linear skeleton, for enabling the ⁇ -unsaturation to bind to the binding region of the fatty acid amide hydrolase while the inhibition subunit A inhibits the fatty acid amide hydrolase.
- C is optionally C1-C10 alkyl.
- heterocyclic pharmacophore is selected from the following group:
- the inhibitor of fatty acid amide hydrolase is represented by the following structure:
- R 1 and R 2 are independently selected from the group consisting of hydrogen, fluoro, chloro, hydroxyl, alkoxy, trifluoromethyl, and alkyl; and "n" is an integer between 2 and 8.
- a further aspect of the invention is directed to processes for inhibiting fatty acid amide hydrolase.
- the process employs the step of contacting the fatty acid amide hydrolase with an inhibiting concentration of an inhibitor of the type described above. Upon contacting the fatty acid amide, the binding subunit C of the inhibitor binds to the binding region of the fatty acid amide hydrolase for enhancing the inhibition activity of the inhibitor.
- Figure 1 illustrates two tables that list the K s for the various compounds tested.
- Figure 2 is a continuation of the second table of Figure 1 that lists the K j 's for the 4- and 5-heteroaryl substituted ⁇ -keto oxazole inhibitors of FAAH.
- Figure 3 illustrates a table of the K j 's of ⁇ -keto oxazolopyridine inhibitors of FAAH.
- Figure 4 illustrates a table showing the systematic variation in the side chain and its effects on the activity of the compounds listed.
- An exemplary head group is used in this series.
- Figure 5 illustrates the aryl-substituted heterocycles 206 and 207 and their method of synthesis from either the 4- or 5-bromo compounds.
- Figure 6 illustrates a table that shows the change in K j 's of the compounds by the presence or absence of a double bond in the C18 tail of ⁇ -keto heterocycle inhibitors of FAAH.
- Figure 7 illustrates a table that shows the effect of modifying the fatty acid side chain of ⁇ -keto oxazolopyridine inhibitors of FAAH on the K j 's of the compounds.
- Figure 8 illustrates a table that shows first generation inhibitors and their
- Figure 9 illustrates a table that shows second generation inhibitors and their IC 50 's with FAAH.
- Figure 10 illustrates a series of reactions that disclose how the substituted oxazole inhibitors are synthesized.
- Figure 11 illustrates a bar graph showing the reduced thermal pain responses 60 minutes following the injection of OL-135 (10 mg/kg, i.p.).
- Figure 12 illustrates a bar graph showing the reduced thermal pain responses 60 minutes following the injection of OL-135 (10 mg/kg, i.p.).
- Figure 13 illustrates a bar graph that shows SR 141716A blocking the analgesic effects of OL-135 in the tail immersion test.
- Figure 14 illustrates a bar graph that shows SR 141716A blocking the analgesic effects of OL-135 in the hot plate test.
- Figure 15 illustrates how the ester is functionalized at the alpha position with fluorine, hydroxyl and trifluoromethyl groups.
- Figure 16 illustrates the methods by which chlorine, alpha-alkyl-alpha- hydroxyl, alpha-alkyl-alpha-trifluoromethyl, and alpha-alkyl-alpha-fluoro groups may be added to an ester.
- Improved competitive inhibitors of FAAH were developed employing an ⁇ -keto heterocyclic pharmacophore and a binding subunit having a ⁇ - unsaturation.
- the ⁇ -keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferably by a hydrocarbon chain.
- the improvement lies in the use of a heterocyclic pharmacophore selected from oxazoles, oxadiazoles, thiazoles, and thiadiazoles that include alkyl or aryl substituents at their 4 and/or 5 positions.
- the improved competitive inhibitors of FAAH display enhanced activity over conventional competitive inhibitors of FAAH which employ non-azole heterocyclic pharmacophores and/or heterocyclic pharmacophores that lack aryl or alkyl substituents.
- the improved competitive inhibitors of FAAH disclosed herein confirm that incorporation of an unsaturation into the fatty acid chain increases inhibitor potency.
- the incorporation of a benzene ring proved to be particularly effective.
- the electrophilic carbonyl was confirmed to be required for potent enzyme inhibition with respect to the competitive inhibitors of FAAH disclosed herein.
- Figure 1 illustrates two tables that list the K j 's for the various compounds tested.
- the first table shows that the oxazole and oxadiazole are over 1000 times more potent than the thiazole. Interestingly, the potency is very nearly recovered by the substitution of another nitrogen in the thiadiazole heterocycle.
- the second table shows the variations in the heterocycle in the 4- and 5-positions of the oxazole head group and its effect on K j .
- Figure 2 is a continuation of the second table in Figure 1.
- One trend seen with the data is the increase in activity with nitrogen-containing heterocycles.
- Figure 3 illustrates a table of the K j 's of ⁇ -keto oxazolopyridine inhibitors of
- Figure 4 illustrates a table showing the modifications in the fatty acid side chain and the effects on K,. The trend is slightly different here than that of the oxazolopyridine inhibitor tested earlier. A saturated dodecanoyl group on this 5- (2-pyridyl)-substituted oxazole gave a lower K j than the favored alkylphenyl side chain. The difference between compounds 185 and 200 is only a factor of two.
- Figure 5 illustrates compounds 206 and 207 and how a palladium- catalyzed cross-coupling reaction is used to synthesize them.
- the Suzuki coupling is accomplished by using catalytic palladium(O) dibenzylidene acetone in the presence of base and the desired aryl or heteroaryl boronic acid (Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2857-2483).
- Figure 6 illustrates a table that shows the change in K j 's of the compounds by the presence or absence of a double bond in the C18 tail of ⁇ -keto heterocycle inhibitors of FAAH.
- the first three compounds show that the unsaturation in the chain is important for binding to such an extent that the binding constant is five- fold greater for the fully saturated chain. Essentially the same result is observed for the next two head groups.
- Figure 7 illustrates a table that shows the effect of modifying the fatty acid side chain of ⁇ -keto oxazolopyridine inhibitors of FAAH on the K j 's of the compounds.
- This table compares the various hydrocarbon tail groups with each other and the general trends are summarized in the lines on the bottom of the chart.
- the best saturated chains are those with between 8 and 12 carbons.
- the phenyl-containing side chains are about 3 times as potent as the saturated side chains with this head group.
- the best K j was 200 pM for this series of compounds.
- Figure 8 illustrates a table that shows first generation inhibitors and their IC 50 's with FAAH.
- the value for the IC 50 is approximately 10 times larger than the corresponding K j 's for this enzyme.
- a trifluoromethyl ketone is included for comparison with the designed inhibitors.
- the lC 50 's correspond well to the K j 's of the compounds.
- compound 118 has both the lowest IC 50 and K j .
- Figure 9 illustrates a table that shows second generation inhibitors and their IC 50 's with FAAH. The second generation inhibitors show more variation in their IC 50 's compared to their corresponding K j 's.
- Figure 10 illustrates a series of reactions that illustrate how the substituted oxazole inhibitors are synthesized.
- the first reaction at the top of the page shows how the 2-position on the oxazole is acylated.
- the oxazole is first lithiated with n- butyllithium, transmetallated with zinc chloride, the cuprate is formed by the addition of copper(l) iodide and then the cuprate is acylated with the acid chloride.
- the detailed procedure is described for compound 162 in the experimental section.
- the second method for the formation of the 2-acyl oxazoles is a standard lithiation and then acylation with the Weinreb amide.
- Compound 144 was synthesized by this method as outlined in the experimental section. The remaining two reactions show the retrosynthesis for the 4- or 5-substituted heterocycle.
- X is a halogen or some other leaving group.
- Figure 13 illustrates a bar graph that shows SR 141716A blocking the analgesic effects of OL-135 in the tail immersion test.
- Figure 14 illustrates a bar graph that shows SR 141716A blocking the analgesic effects of OL-135 in the hot plate test.
- Figure 15 illustrates how the ester is functionalized at the alpha position with fluorine, hydroxyl and trifluoromethyl groups.
- An asymmetric method for making a chiral alpha-fluoro ester is given, but one familiar with the art will know how to accomplish making the trifluoromethyl derivative in an asymmetric fashion. These methods assume that any functional groups present in "R" have suitable protection.
- Figure 16 illustrates the methods by which chlorine, alpha-alkyl-alpha- hydroxyl, alpha-alkyl-alpha-trifluoromethyl, and alpha-alkyl-alpha-fluoro groups may be added to an ester. Depending on what "R" is, some of these esters or the corresponding acids may be commercially available.
- a Mitsunobu reaction is done to obtain the alpha-chloro compound from the corresponding alpha-hydroxy ester.
- An asymmetric hydroxylation of an enolate of an alpha-alkyl ester is accomplished by using an asymmetric oxaziridine (I). The last two products in this figure are obtained as racemates.
- the reaction was diluted with EtOAc (10 mL), and washed with 15% aqueous NH 4 OH (1 x 10 mL), H 2 O (1 x 10 mL), and saturated aqueous NaCI (1 x 10 mL).
- the organic layer was dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure.
- the reaction was diluted with EtOAc (10 mL), and washed with 15%) aqueous NH 4 OH (1 x 10 mL), H 2 O (1 x 10 mL), and saturated aqueous NaCI (1 x 10 mL).
- the organic layer was dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure.
- the reaction was diluted with EtOAc (10 mL), and washed with 15% aqueous NH 4 OH (1 x 10 mL), H 2 O (1 x 10 mL), and saturated aqueous NaCI (1 x 10 mL).
- the organic layer was dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure.
- Triphenylphosphine (69.3 mg, 0.264 mmol, 5.0 equiv) and carbon tetrabromide (87.6 mg, 0.264 mmol, 5.0 equiv) were added to a solution of 1 -hydroxy-1 -[5-(2-pyridyl)oxazol-2-yl]-9(Z)- octadecene (26, 21.8 mg, 0.053 mmol) in dichloromethane (2.0 mL) at 0°C (A similar reaction was reported: Bohlmann, F.; et al. Chem.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60327640T DE60327640D1 (en) | 2002-10-08 | 2003-10-08 | |
AT03759771T ATE431342T1 (en) | 2002-10-08 | 2003-10-08 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE |
CA002501575A CA2501575A1 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
AU2003275493A AU2003275493A1 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
JP2004543576A JP4628789B2 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
EP03759771A EP1549624B1 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
EA200500633A EA008767B1 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
MXPA05003762A MXPA05003762A (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase. |
BR0314980-3A BR0314980A (en) | 2002-10-08 | 2003-10-08 | Fatty Acid Amide Hydrolase Inhibitors |
US10/528,552 US7662971B2 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41724702P | 2002-10-08 | 2002-10-08 | |
US60/417,247 | 2002-10-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004033652A2 true WO2004033652A2 (en) | 2004-04-22 |
WO2004033652A3 WO2004033652A3 (en) | 2004-09-16 |
Family
ID=32093990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/031975 WO2004033652A2 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
Country Status (15)
Country | Link |
---|---|
US (1) | US7662971B2 (en) |
EP (2) | EP2093220A3 (en) |
JP (1) | JP4628789B2 (en) |
KR (1) | KR20050070041A (en) |
CN (1) | CN1703407A (en) |
AT (1) | ATE431342T1 (en) |
AU (1) | AU2003275493A1 (en) |
BR (1) | BR0314980A (en) |
CA (1) | CA2501575A1 (en) |
DE (1) | DE60327640D1 (en) |
EA (1) | EA008767B1 (en) |
ES (1) | ES2325686T3 (en) |
MX (1) | MXPA05003762A (en) |
WO (1) | WO2004033652A2 (en) |
ZA (1) | ZA200501837B (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004039326A1 (en) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Treatment of neurodegenerative diseases, specifically Alzheimer's disease and Down syndrome, uses a chemical/biological substance which inhibits fatty acid amide hydrolase without inhibiting cyclooxygenase-1 and/or 2 |
WO2007061862A2 (en) | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
EP1812427A1 (en) * | 2004-10-15 | 2007-08-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
WO2007098142A2 (en) | 2006-02-17 | 2007-08-30 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
WO2008030532A2 (en) * | 2006-09-08 | 2008-03-13 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
EP2051964A2 (en) * | 2006-07-28 | 2009-04-29 | University of Connecticut | Fatty acid amide hydrolase inhibitors |
US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
US7560570B2 (en) | 2000-03-27 | 2009-07-14 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
US7598249B2 (en) | 2004-12-30 | 2009-10-06 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
WO2009154785A2 (en) * | 2008-06-19 | 2009-12-23 | The Scripps Research Institute | C4-substituted alpha-keto oxazoles |
WO2010005572A2 (en) * | 2008-07-09 | 2010-01-14 | The Scripps Research Institute | Alpha-keto heterocycles as faah inhibitors |
WO2010017079A1 (en) | 2008-08-04 | 2010-02-11 | Merck & Co., Inc. | Oxazole derivatives useful as inhibitors of faah |
US7662971B2 (en) | 2002-10-08 | 2010-02-16 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
WO2010068453A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
WO2011030798A1 (en) | 2009-09-09 | 2011-03-17 | 大日本住友製薬株式会社 | 8-oxodihydropurine derivative |
WO2011060026A1 (en) | 2009-11-12 | 2011-05-19 | Jansen Pharmaceutica Nv | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
WO2011139951A1 (en) | 2010-05-03 | 2011-11-10 | Janssen Pharmaceutica Nv | Modulators of fatty acid amide hydrolase |
US8343970B2 (en) | 2010-03-12 | 2013-01-01 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US8598202B2 (en) | 2008-02-19 | 2013-12-03 | Janssen Pharmaceutica Nv | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
US9493447B2 (en) | 2014-04-28 | 2016-11-15 | Omeros Corporation | Optically active PDE10 inhibitor |
EP3095787A1 (en) * | 2015-05-22 | 2016-11-23 | Universiteit Leiden | Pharmaceutically active compounds as dag-lipase inhibitors |
US9597318B2 (en) | 2009-10-02 | 2017-03-21 | Avexxin As | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders |
US9650368B2 (en) | 2014-04-28 | 2017-05-16 | Omeros Corporation | Processes and intermediates for the preparation of a PDE10 inhibitor |
US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
US10150781B2 (en) | 2014-08-01 | 2018-12-11 | Avexxin As | 2-oxothiatole compounds having activity as CPLA2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders |
US10259801B2 (en) | 2013-01-29 | 2019-04-16 | Avexxin As | Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds |
US11439625B2 (en) | 2016-03-14 | 2022-09-13 | Avexxin As | Combination therapy for proliferative diseases |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865205B1 (en) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | ARYLOXYALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
FR2866886B1 (en) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | ARYL-AND HETEROARYL-AKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
US8372823B2 (en) | 2007-05-25 | 2013-02-12 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
CA2689148A1 (en) * | 2007-05-31 | 2008-12-11 | The Scripps Research Institute | Tricyclic inhibitors of fatty acid amide hydrolase |
BR122013027950A2 (en) * | 2008-12-24 | 2019-12-10 | BIAL PORTELA & Cª S A | pharmaceutical compounds |
AR076687A1 (en) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | ISOXAZOLINS AS INHIBITORS OF THE AMIDAHIDROLASA OF FATTY ACIDS AND PHARMACEUTICAL COM-POSITIONS CONTAINING THEM |
CN102858338A (en) * | 2010-01-28 | 2013-01-02 | 默沙东公司 | Pharmaceutical Compositions For The Treatment Of Pain And Other Indicatons |
ES2888231T3 (en) * | 2010-09-20 | 2022-01-03 | Sirna Therapeutics Inc | Low molecular weight cationic lipids for oligonucleotide delivery |
CN102964311B (en) * | 2011-09-01 | 2016-03-09 | 大丰海嘉诺药业有限公司 | A kind of method of synthesizing 4-methyl-5-Wan Yang Ji oxazole |
CA2864259C (en) * | 2012-02-17 | 2019-06-11 | Epitech Group S.R.L. | Compositions and methods for the modulation of specific amidases for n-acylethanolamines for use in the therapy of inflammatory diseases |
DK3063144T3 (en) | 2013-11-01 | 2021-10-25 | Boehringer Ingelheim Animal Health Usa Inc | ANTIPARASITARY AND PESTICID-ISOXAZOLINE COMPOUNDS |
US20160244860A1 (en) * | 2015-02-20 | 2016-08-25 | Cytec Industries Inc. | Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002046129A2 (en) | 2000-10-26 | 2002-06-13 | Abbott Laboratories | Inhibitors of histone deacetylase |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA19269A1 (en) * | 1980-09-16 | 1982-04-01 | Lilly Co Eli | IMPROVEMENT RELATING TO N-ARYLBENZAMIDE DERIVATIVES. |
US5672709A (en) * | 1994-10-24 | 1997-09-30 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
US6462054B1 (en) | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
AU2003275493A1 (en) | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
-
2003
- 2003-10-08 AU AU2003275493A patent/AU2003275493A1/en not_active Abandoned
- 2003-10-08 JP JP2004543576A patent/JP4628789B2/en not_active Expired - Fee Related
- 2003-10-08 EP EP09006391A patent/EP2093220A3/en not_active Withdrawn
- 2003-10-08 US US10/528,552 patent/US7662971B2/en not_active Expired - Fee Related
- 2003-10-08 DE DE60327640T patent/DE60327640D1/de not_active Expired - Lifetime
- 2003-10-08 KR KR1020057006019A patent/KR20050070041A/en not_active Application Discontinuation
- 2003-10-08 EA EA200500633A patent/EA008767B1/en unknown
- 2003-10-08 EP EP03759771A patent/EP1549624B1/en not_active Expired - Lifetime
- 2003-10-08 AT AT03759771T patent/ATE431342T1/en not_active IP Right Cessation
- 2003-10-08 ES ES03759771T patent/ES2325686T3/en not_active Expired - Lifetime
- 2003-10-08 CA CA002501575A patent/CA2501575A1/en not_active Abandoned
- 2003-10-08 CN CNA2003801009944A patent/CN1703407A/en active Pending
- 2003-10-08 WO PCT/US2003/031975 patent/WO2004033652A2/en active Application Filing
- 2003-10-08 BR BR0314980-3A patent/BR0314980A/en not_active IP Right Cessation
- 2003-10-08 MX MXPA05003762A patent/MXPA05003762A/en not_active Application Discontinuation
-
2005
- 2005-03-03 ZA ZA200501837A patent/ZA200501837B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002046129A2 (en) | 2000-10-26 | 2002-06-13 | Abbott Laboratories | Inhibitors of histone deacetylase |
Non-Patent Citations (11)
Title |
---|
A DONDONI ET AL., J ORG. CHEM, vol. 52, 1987, pages 3413 - 3420 |
B.F. CRAVATT ET AL., NATURE, vol. 384, 1996, pages 83 - 87 |
BOGER ET AL., PNAS, vol. 97, no. 10, 2000, pages 5044 - 5049 |
BOHLMANN, F. ET AL., CHEM. BER., vol. 109, 1976, pages 1586 - 1588 |
D.K. GIANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 2238 - 2242 |
GIARDINA ET AL., J. MED. CHEM., vol. 40, 1997, pages 1794 - 1807 |
K. CONDE- FRIEBOES ET AL., J. AM. CHEM. SOC., vol. 118, 1996, pages 5519 - 5525 |
KIUCHI, F. ET AL., CHEM. PHARM. BULL., vol. 45, 1997, pages 685 - 696 |
MIYAURA, N.; SUZUKI, A., CHEM. REV., vol. 95, 1995, pages 2857 - 2483 |
SAIKACHI, H. ET AL., CHEM. PHARM. BULL., vol. 27, 1979, pages 793 - 796 |
THEILIG, G., CHEM. BER., vol. 86, 1953, pages 96 - 109 |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7560570B2 (en) | 2000-03-27 | 2009-07-14 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
US7662971B2 (en) | 2002-10-08 | 2010-02-16 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
DE102004039326A1 (en) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Treatment of neurodegenerative diseases, specifically Alzheimer's disease and Down syndrome, uses a chemical/biological substance which inhibits fatty acid amide hydrolase without inhibiting cyclooxygenase-1 and/or 2 |
EP1812427A1 (en) * | 2004-10-15 | 2007-08-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
EP1812427A4 (en) * | 2004-10-15 | 2009-10-14 | Scripps Research Inst | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
US7351724B2 (en) | 2004-10-15 | 2008-04-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
US8530476B2 (en) | 2004-12-30 | 2013-09-10 | Janssen Pharmaceutica Nv | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
US9169224B2 (en) | 2004-12-30 | 2015-10-27 | Janssen Pharmaceutica Nv | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
EP2937341A1 (en) | 2004-12-30 | 2015-10-28 | Janssen Pharmaceutica N.V. | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
US7598249B2 (en) | 2004-12-30 | 2009-10-06 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
WO2007061862A2 (en) | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
WO2007098142A3 (en) * | 2006-02-17 | 2008-09-04 | Scripps Research Inst | Oxazole ketones as modulators of fatty acid amide hydrolase |
EP1983994A2 (en) * | 2006-02-17 | 2008-10-29 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
US7915270B2 (en) * | 2006-02-17 | 2011-03-29 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
WO2007098142A2 (en) | 2006-02-17 | 2007-08-30 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
EP1983994A4 (en) * | 2006-02-17 | 2011-10-12 | Scripps Research Inst | Oxazole ketones as modulators of fatty acid amide hydrolase |
EP2051964A2 (en) * | 2006-07-28 | 2009-04-29 | University of Connecticut | Fatty acid amide hydrolase inhibitors |
US9102622B2 (en) | 2006-07-28 | 2015-08-11 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
EP2051964A4 (en) * | 2006-07-28 | 2012-03-07 | Univ Connecticut | Fatty acid amide hydrolase inhibitors |
US8268817B2 (en) * | 2006-09-08 | 2012-09-18 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
WO2008030532A2 (en) * | 2006-09-08 | 2008-03-13 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
WO2008030532A3 (en) * | 2006-09-08 | 2008-09-12 | Scripps Research Inst | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
US8598202B2 (en) | 2008-02-19 | 2013-12-03 | Janssen Pharmaceutica Nv | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
WO2009154785A2 (en) * | 2008-06-19 | 2009-12-23 | The Scripps Research Institute | C4-substituted alpha-keto oxazoles |
US20110184026A1 (en) * | 2008-06-19 | 2011-07-28 | Boger Dale L | C4-substituted alpha-keto oxazoles |
WO2009154785A3 (en) * | 2008-06-19 | 2010-04-01 | The Scripps Research Institute | C4-substituted alpha-keto oxazoles |
WO2010005572A3 (en) * | 2008-07-09 | 2010-05-14 | The Scripps Research Institute | Alpha-keto heterocycles as faah inhibitors |
US8987312B2 (en) | 2008-07-09 | 2015-03-24 | The Scripps Research Institute | Alpha-keto heterocycles as FAAH inhibitors |
WO2010005572A2 (en) * | 2008-07-09 | 2010-01-14 | The Scripps Research Institute | Alpha-keto heterocycles as faah inhibitors |
CN102171196A (en) * | 2008-08-04 | 2011-08-31 | 默沙东公司 | Oxazole derivatives useful as inhibitors of FAAH |
US8673941B2 (en) | 2008-08-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of FAAH |
US9045467B2 (en) | 2008-08-04 | 2015-06-02 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of FAAH |
CN102171196B (en) * | 2008-08-04 | 2015-03-25 | 默沙东公司 | Azole derivatives as inhibitors of fatty acid amide hydrolase |
WO2010017079A1 (en) | 2008-08-04 | 2010-02-11 | Merck & Co., Inc. | Oxazole derivatives useful as inhibitors of faah |
WO2010068453A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
US8877769B2 (en) | 2008-11-25 | 2014-11-04 | Janseen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
US8901111B2 (en) | 2009-06-05 | 2014-12-02 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
WO2011030798A1 (en) | 2009-09-09 | 2011-03-17 | 大日本住友製薬株式会社 | 8-oxodihydropurine derivative |
US10370344B2 (en) | 2009-10-02 | 2019-08-06 | Avexxin As | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders |
US9597318B2 (en) | 2009-10-02 | 2017-03-21 | Avexxin As | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders |
WO2011060026A1 (en) | 2009-11-12 | 2011-05-19 | Jansen Pharmaceutica Nv | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
US8343970B2 (en) | 2010-03-12 | 2013-01-01 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US8685975B2 (en) | 2010-03-12 | 2014-04-01 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US10106516B2 (en) | 2010-03-12 | 2018-10-23 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
US8940745B2 (en) | 2010-05-03 | 2015-01-27 | Janssen Pharmaceutica Nv | Modulators of fatty acid amide hydrolase |
US9688664B2 (en) | 2010-05-03 | 2017-06-27 | Janssen Pharmaceutica Nv | Modulators of fatty acid amide hydrolase |
WO2011139951A1 (en) | 2010-05-03 | 2011-11-10 | Janssen Pharmaceutica Nv | Modulators of fatty acid amide hydrolase |
US10259801B2 (en) | 2013-01-29 | 2019-04-16 | Avexxin As | Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds |
US11034666B2 (en) | 2013-01-29 | 2021-06-15 | Avexxin As | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds |
US11691959B2 (en) | 2013-01-29 | 2023-07-04 | Avexxin As | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds |
US9650368B2 (en) | 2014-04-28 | 2017-05-16 | Omeros Corporation | Processes and intermediates for the preparation of a PDE10 inhibitor |
US9850238B2 (en) | 2014-04-28 | 2017-12-26 | Omeros Corporation | Optically active PDE10 inhibitor |
US9493447B2 (en) | 2014-04-28 | 2016-11-15 | Omeros Corporation | Optically active PDE10 inhibitor |
US10150781B2 (en) | 2014-08-01 | 2018-12-11 | Avexxin As | 2-oxothiatole compounds having activity as CPLA2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders |
US10851114B2 (en) | 2014-08-01 | 2020-12-01 | Avexxin As | 2-oxothiatole compounds having activity as cPLA2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders |
US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
WO2016188972A1 (en) * | 2015-05-22 | 2016-12-01 | Universiteit Leiden | Pharmaceutically active compounds as dag-lipase inhibitors |
EP3095787A1 (en) * | 2015-05-22 | 2016-11-23 | Universiteit Leiden | Pharmaceutically active compounds as dag-lipase inhibitors |
US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
US11439625B2 (en) | 2016-03-14 | 2022-09-13 | Avexxin As | Combination therapy for proliferative diseases |
Also Published As
Publication number | Publication date |
---|---|
DE60327640D1 (en) | 2009-06-25 |
US20060111359A1 (en) | 2006-05-25 |
MXPA05003762A (en) | 2005-07-22 |
CN1703407A (en) | 2005-11-30 |
BR0314980A (en) | 2005-08-09 |
EA200500633A1 (en) | 2005-10-27 |
ES2325686T3 (en) | 2009-09-14 |
KR20050070041A (en) | 2005-07-05 |
EP2093220A2 (en) | 2009-08-26 |
US7662971B2 (en) | 2010-02-16 |
JP2006502229A (en) | 2006-01-19 |
EP1549624A4 (en) | 2006-09-20 |
EA008767B1 (en) | 2007-08-31 |
CA2501575A1 (en) | 2004-04-22 |
AU2003275493A1 (en) | 2004-05-04 |
EP1549624B1 (en) | 2009-05-13 |
ATE431342T1 (en) | 2009-05-15 |
EP2093220A3 (en) | 2009-11-11 |
ZA200501837B (en) | 2006-06-28 |
JP4628789B2 (en) | 2011-02-09 |
EP1549624A2 (en) | 2005-07-06 |
WO2004033652A3 (en) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1549624B1 (en) | Inhibitors of fatty acid amide hydrolase | |
JP4931893B2 (en) | PPAR activating compound and pharmaceutical composition containing the same | |
JP6049791B2 (en) | Activator of peroxisome proliferator activated receptor δ | |
Malamas et al. | New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties | |
AU728812B2 (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
JP3997491B2 (en) | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | |
KR20010085340A (en) | Substituted Oxazoles and Thiazoles Derivatives as hPPAR Gamma and hPPAR Alpha Activators | |
US8410151B2 (en) | Aminomethyl benzene derivatives | |
CA2696232C (en) | Protein tyrosine phosphatase 1b inhibitor, preparation methods and uses thereof | |
JP2006516254A (en) | Fused heterocyclic derivatives as PPAR modulators | |
AU2007301607A1 (en) | Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | |
JPWO2008016175A1 (en) | Peroxisome proliferator-activated receptor activator | |
WO2015160772A1 (en) | Tetrahydro-benzoimidazolyl modulators of tgr5 | |
EP1503997A1 (en) | Cysteine protease inhibitors | |
MXPA02011609A (en) | Heterocyclic compounds. | |
Shibata et al. | Synthesis and Structure–Activity Relationships of Novel Zwitterionic Compounds as Peroxisome Proliferator Activated Receptor α/γ Dual Agonists with Improved Physicochemical Properties | |
WO2016017699A1 (en) | Azole carboxylic acid derivative | |
FR2865207A1 (en) | New N-thiazolyl-amides, useful for treating e.g. dementia and neurodegenerative diseases, are inhibitors of the formation of beta-amyloid peptide A4 | |
Shahabi et al. | Synthesis and Characterization of Novel Substituted of 1, 3, 4-thiadiazole and 1, 3, 4-oxadiazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 166969 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 736/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/01837 Country of ref document: ZA Ref document number: 200501837 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003759771 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A09944 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2501575 Country of ref document: CA Ref document number: 2003275493 Country of ref document: AU Ref document number: 1020057006019 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004543576 Country of ref document: JP Ref document number: PA/a/2005/003762 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 539712 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200500633 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057006019 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003759771 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006111359 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10528552 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10528552 Country of ref document: US |